Mad Money host Jim Cramer speaks with James Foster about the Company’s Q2 earnings and why the work we do is so important.
At a facility on the outskirts of Charleston, South Carolina, Charles River Endosafe® extracts the blood from horseshoe crabs. Charles River is one of four companies in the US that utilize horseshoe crabs’ blood to manufacture Limulus Amebocyte Lysate (LAL), which is used for the detection and quantification of bacterial endotoxins.
Limulus amebocyte lysate (LAL), a reagent that utilizes clotting enzymes extracted from horseshoe crab blood, is among the most accurate and reliable indicators of bacteria. Charles River continues to serve as an advocate for the optimal usage of LAL and conservation of this creature.
Many pharmaceutical companies are salvaging failed compounds and seeing whether these drugs might have other indications, particularly after an increasing number of previously shelved compounds have been repurposed.
To move cell-based therapies into the clinic, academic researchers may benefit by consulting researchers outside of academia and the biopharma industry.
Arguably, the biggest challenge in making biologics is flagging unwanted host-cell proteins (HCPs) that inevitably show up in the finished product. While nano in scale, these trace amounts can be highly immunogenic and can ultimately sink a potential biopharmaceutical. As a result, manufacturers must work hard to identify and control any impurities in the final product.
In this interview, James Foster discusses the recent acquisitions, future plans, changing R&D needs and market trends in preclinical outsourcing.
Mad Money host Jim Cramer speaks with James Foster on the Company’s turnaround and planned acquisition of the contract research division of Galapagos NV.
The area’s largest preclinical research organization just got a little larger with the acquisition of two European firms. But what CEO Jim Foster said about the reason for the acquisitions says a lot about both contract research organizations and where biotech in general is headed.
Charles River Laboratories International Inc. announced it will pay $179 million to buy a pair of European drug-targeting businesses that will help it expand its capabilities as a contract research organization for pharmaceutical and biotechnology companies.